Why COVID-19 trials should be blinded (as any other one)

Authors

  • Rafael Leite Pacheco Centro Universitário São Camilo; Universidade Federal de São Paulo (Unifesp)
  • Ana Luiza Cabrera Martimbianco Centro Universitário São Camilo; Universidade Metropolitana de Santos (UNIMES).
  • Carolina de Oliveira Cruz Latorraca Universidade Federal de São Paulo (Unifesp).
  • Rachel Riera Núcleo de Avaliação de Tecnologias em Saúde, Hospital Sírio-Libanês (NATS-HSL); Universidade Federal de São Paulo (Unifesp).

DOI:

https://doi.org/10.17267/2675-021Xevidence.v2i1.2841

Keywords:

Blinding. Clinical trials. COVID-19.

Downloads

Download data is not yet available.

Downloads

Published

04/01/2020

Issue

Vol. 2 No. 1 (2020)

Section

Concept Articles

License

The authors retain copyrights, transferring to the Journal of Evidence-Based Healthcare only the right of first publication. This work is licensed under a Creative Commons Attribution 4.0 International License.

Creative Commons License

How to Cite

1.
Pacheco RL, Martimbianco ALC, Latorraca C de OC, Riera R. Why COVID-19 trials should be blinded (as any other one). Evidence [Internet]. 2020 Apr. 1 [cited 2024 Nov. 23];2(1):25-7. Available from: https://journals.bahiana.edu.br/index.php/evidence/article/view/2841

Most read articles by the same author(s)